|

Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities

RECRUITINGPhase 1Sponsored by Beijing Tongren Hospital
Actively Recruiting
PhasePhase 1
SponsorBeijing Tongren Hospital
Started2025-03-15
Est. completion2027-03-31
Eligibility
Age1 Year – 18 Years
Healthy vol.Accepted

Summary

Pediatric soft tissue sarcomas (STS) are a group of malignant tumors originating from primitive mesenchymal tissues and account for approximately 7% of childhood cancers. STS are broadly classified into rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). RMS accounts for approximately one half of pediatric STS. As reported, PAX fusion-positive RMS is more aggressive than fusion-negative RMS, with higher metastatic potential and poorer prognosis. Based on the unmet therapeutic need in pediatric sarcoma with PAX-family abnormalities, this study is intended to evaluate the preliminary safety and antitumor activity of entinostat with or without chemontherapy.

Eligibility

Age: 1 Year – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Age \>1 year and ≤18 years.
2. Histologically confirmed malignant soft tissue sarcoma that is PAX3-FOXO1- or PAX7-FOXO1-fusion positive or has another PAX-family gene abnormality.
3. Clinical disease status: (a) monotherapy cohort: completion of standard backbone chemotherapy and/or radiotherapy with a favorable clinical response (CR or PR); (b) combination cohort: inadequate response following standard chemotherapy and/or radiotherapy, or recurrent/progressive disease.
4. Karnofsky Performance Status (KPS) ≥50 or Lansky Performance Status (LPS) ≥50.
5. Adequate bone marrow function: ANC ≥0.5 × 10\^9/L, platelet count ≥50 × 10\^9/L, hemoglobin ≥70 g/L, and WBC ≥1.5 × 10\^9/L, with values not exceeding the upper limit of normal.
6. Life expectancy of at least 6 months.
7. Written informed consent obtained.

Exclusion Criteria:

1. Previous hematopoietic stem cell transplantation or organ transplantation.
2. Participation in another drug clinical trial within 2 months before enrollment.
3. Uncontrolled infection or body temperature ≥38°C.
4. Total bilirubin, ALT, and AST \>2.5 × the upper limit of normal.
5. Serum creatinine \>2.0 × the upper limit of normal.
6. Any other condition considered by the investigator to constitute a contraindication to study participation.

Conditions2

CancerSoft Tissue Sarcoma

Interventions2

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.